miR-624 upregulated YAP and HIF1α to enhance ESCC cell resistance to CIS and PT through downregulation of ARRDC3 (Figure 6), thus identifying the role of the miR-624/ARRDC3/YAP/HIF1α axis in chemoresistance of ESCC cells to CIS and PT, offering novel therapeutic targets to inhibit resistance of ESCC cells to chemotherapy. Here, HIF1A is linked to esophageal squamous cell carcinoma.